The global BiTE antibody industry by 2025

Dublin, 23 February 2021 (GLOBE NEWSWIRE) – The report “Global BiTE Antibody Market, Price, Sales and Clinical Trials Insight 2025” was added in’s offer.

This report provides an overview of the widespread use of the market and how it has managed to overcome the challenges that have been widespread in the cancer therapy market over time. The research report summarizes the scientific advances that have led to the integration of the applications of monoclonal antibodies into bispecific antibodies against cancer and making it widely acceptable against different types of cancer indications. It is analyzed that major current trends, opportunities and desirable achievements related to the market of bispecific anti-cancer antibody therapy are set to provide all essential constructive applications in terms of health benefits, making the market a highly debated cancer therapy in the current pharmaceutical era. industry.

The unique BITE antibody market approach, widely known as the bispecific cancer antibody market, involves an innovative genetic engineering methodology to develop an antibody that can simultaneously target two different epitopes, making the entire cancer targeting process more accurate compared to monoclonal therapy. It is also believed that connecting the entire market with strong and robust clinical pipelines and research activities in the past, as well as today, completely revolutionizes the overall market opportunities in the market for bispecific antibodies to cancer.

It is estimated that next-generation market opportunities held within therapy with respect to health benefits and the setting of therapy as a standard treatment regimen will cause a significant increase in the market growth rate compared to other cancer therapies. The large penetration of drugs on bispecific antibodies against cancer against various indications of cancer also leads to certain changes in the entire cancer market. Some of the parameters believed to be responsible for launching the market in the next few years are: increasing cancer cases, the advent of innovative technologies, awareness of the application of antibodies to bispecific cancer and a wide range of drugs available for various diseases.

According to the findings of the report “Global Antibody Market on BiTE, Price, Sales and Clinical Trials 2025”, it is observed that the entire market is associated with hundreds of high-performance drugs that have led to a decline in global cancer mortality. Ease of drug availability and an innovative approach to increasing target specificity estimate that it will cause a radical shift in overall market acceptance, which has long been observed for only some of the prominent cancer therapies, such as chemotherapy. It is observed that the entire market is maturing rapidly globally as hundreds of bio-pharmaceutical companies and research centers engage in market expansion by approving more powerful drugs for commercial use. It is believed that some of the already pioneering market leaders are causing a huge acceleration, which is unsurpassed and unimaginable for the therapy discovered several decades ago. It is analyzed that future market conditions will make the market recognized as a standard and dominant treatment regimen for millions of patients.

Key topics:

1. Bispecific antibodies: Next-generation antibody therapy
1.1 History of bispecific antibodies
1.2 Examination of bispecific antibodies

2. Advantages of bispecific antibody over monoclonal antibodies

3. BiTE (Bispecific T Cell Engager) – a new era in cancer immunotherapy

4. BiTE structure and design
4.1 Construction of single-chain variable antibody fragments
4.2 Bispecific expression and production of scFv antibodies

5. BiTE antibody – mode of action
5.1 BiTE redirected the lysis of target cells
5.2 BiTE activates T cells
5.3 Formation of lytic synapse by BiTE

6. Blinatumomab (Blincyto): First approved BiTE antibody
6.1 Clinical trials, approval and patenting
6.2 Design and mechanism of action
6.3 Adverse drug reactions and management

7. Global indicators of clinical trials of BiTE antibodies
7.1 By phases
7.2 Company
7.3 By country
7.4 By indication
7.5 according to the patient segment

8. Global BiTE clinical pipeline by company, indication and phase
8.1 Preclinical
8.2 Phase I

9. Global BiTE Antibody Market Overview
9.1 Current market scenario
9.2 Blincyto fee policy

10. Blincyto – Dosage and market sales analysis
10.1 Dosage of Blincyt in B-ALL
10.2 Current market sales analysis

11. Clinical pipeline of bispecific T-cell switches

12. T-cell bridging to tumors: CAR vs BiTE

13. BiTE: Research and development in progress
13.1 BiTe immunotherapeutic treatment for relapsed refractory multiple myeloma
13.2 New DLTE3 targeted BiTE shows antitumor activity in small cell lung cancers
13.3 Preliminary efficacy of AMG 160 in metastatic castration – resistant prostate cancer

14. Global bispecific market dynamics of T-Cell Engagers
14.1 Favorable market parameters
14.2 Challenges of commercialization

15. Prospects for the future of the global BiTE market

16. Competitive landscape
16.1 Amgen
16.2 Bayers
16.3 Micromet
16.4 Psioxus Therapeutics
16.5 Y Biologics

For more information on this report, visit

Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900